Skip to main content
Clinics and Practice logoLink to Clinics and Practice
. 2011 Apr 12;1(1):e11. doi: 10.4081/cp.2011.e11

Acute promyelocytic leukemia, hypogranular variant: a rare presentation

Kafil Akhtar 1, Shamshad Ahmad 1, Rana K Sherwani 1
PMCID: PMC3981211  PMID: 24765265

Abstract

Early diagnosis of acute promyelocytic leukemia (APL) is essential because of its associated life threatening coagulopathy and unique response to all trans-retinoic acid (ATRA) therapy. The characteristic cell morphology supplemented by cytochemistry offers the most rapid means for diagnosis. Here we describe a rare case of acute promyelocytic leukemia-hypogranular variant that poses particular diagnostic challenge.

Key words: acute promyelocytic leukemia, hypogranular variant, cytochemistry.

Introduction

Acute promyelocytic leukemia (APL), M3 subtype of acute myeloid leukemia (AML) is characterized in the majority of cases by proliferation of neoplastic hypergranlar promyelocytes and blast.1 The biological and clinical heterogenicity of APL is based on the clinical presentation of the disease and various characteristics of leukemic cells at diagnosis. Patients with APL typically present with low white blood counts, peripheral blood cytopenias and coagulopathy.2 A morphologic hypogranular variant is encountered with less frequent.3 Here we report a case of APL- hypogranular variant that poses particular diagnostic challenge because of its atypical morphology.

Case Report

A 30-year-old male presented with severe anemia, bilateral subconjunctival haemorrhage and petechial skin rashes. Clinical examination revealed multiple ecchymosis, right cervical lymphadenopathy but no hepatosplenomegaly. Hematological examination showed a low hemoglobin count (9.0 gm%), total leucocyte count was markedly raised (80,000 cells/cu) with predominance of promyelocytes and blasts on differential count and platelet count of 34,000 cells/cu. Coagulation studies showed prothrombin time (PT) to be 15.2 s, activated partial thromboplastin time (APTT) −27.5 s and fibrinogen −1.05 g/L. Chest X-rays and an echocardiogram were normal.

Peripheral blood cytomorphology showed promyelocytes with a characteristic bilobed or reniform nucleus; with majority of the cells either devoid of granules or contained only a few fine azurophil granules (Figure 1). The bone marrow aspirate was markedly hypercellular and frankly leukemic, 95% cells were blasts with bilobulated nucleus and fine dust like cytoplasmic granules. The leukemic cells showed a strong myeloperoxidase reaction (Figure 2). Molecular cytogenetic analysis by fluorescent in situ hybridization (FISH) was used to investigate chromosomal abnormalities associated with the leukemic process and found out to be translocation of chromosome 15 and 17, i.e., t(15;17) (Figure 3).

Figure 1.

Figure 1

Peripheral blood film showing circulating promyelocytes with characteristically bilobed nucleus and hypogranular cytoplasm. Leishman stain × 1000.

Figure 2.

Figure 2

Cytochemistry result showing strong myeloperoxidase posi.

Figure 3.

Figure 3

Acute promyelocytic leukemia: FISH technique shows chromosomal translocation, t(15;17).

In view of the atypical blasts morphology, a provisional diagnosis of hypogranular variant of AML-M3v was suggested. The patient was immediately started on all trans-retinoic acid (ATRA) and cytarabine and is progressing well after 12 months of follow up period.

Discussion

This case report emphasizes the importance of a high index of suspicion for the diagnosis of acute promyelocytic leukemia, the hypogranular variant in particular. Overall, classical hypergranular and hypogranular variant constitute 5–8% of cases of AML in different Western Series,4 and hypogranular variant comprises 1/3 of all cases of acute promyelocytic leukemia.5 Both APL subtypes share a common pathogenic pathway, namely presence of t(15;17)(q21;q22) translocation and a similar clinical picture, namely consumptive coagulopathy at presentation (Table 1). They are responsive to differentiation therapy with all trans-retinoic acid (ATRA) and compete remission in seen in >80% cases.6,7 Quite similarly our case is progressing well after 6 months of follow of period. Grignani et al.8 have asserted that FISH is rapid and cost-effective when compared to classical cytogenetics, to establish diagnoses for the specific translocation t(15;17) in APL patients. Proper diagnosis of APL is critical for two reasons: i) anticipating complications due to disseminated intra-vascular coagulation (DIC) and ii) treatment with Tretinoin (all-trans-retinoic-acid) for complete remission in about 80% of patients.7

Table 1. A comparison of classical hypergranular and hypogranular variant.

Hypergranular Hypogranular
Definition AML subtype in which maturation arrests in promyelocytic stage.
Clinical Disseminated intravascular coagulation/consumption coagulopathy
WBC Low High
Nucleus Round to oval Bilobed
Cytoplasm Densely packed large azurophilic granules, multiple auer rods, aggot cells. Granules apparently absent, typical hypergranular promyelocytes exists in small number
Cytochemistry Myeloperoxidase and Sudan Black-B strongly positive
Immunophenotype CD 33+, CD 34−/+, CD15−/+; CD 56−/+; HLA DR positive CD 13+, CD 34+, HLA DR negative
Cytogenetics t(15;17) (q22;q12)

To conclude, the therapeutic option and prognostic implication in APL-variant has made early diagnosis of paramount clinical significance. Although, the cytogenetic and immunophenotypic signature should be referred to in diagnosing APL, from the practical point of view, other parameters, such as cytomorphology and cytochemistry are still important tools for rapid recognition of APL.

References

  • 1.Sucić M, Zadro R, Burazer B, et al. Acute promyelocytic leukemia M3: cytomorphologic, immunophenotypic, cytogenetic, and molecular variants. J Hematother Stem Cell Res. 2002;11:941–50. doi: 10.1089/152581602321080600. [DOI] [PubMed] [Google Scholar]
  • 2.Kaito K, Otsubo H, Dobashi N, et al. CD2+ tetraploid acute promyelocytic leukemia variant with double (15;17) translocations. Int J Hematol. 2005;81:29–31. doi: 10.1532/ijh97.04104. [DOI] [PubMed] [Google Scholar]
  • 3.Tallman MS, Rowe JM. Long-term follow-up and potential for cure in acute promyelocytic leukaemia. Best Pract Res Clin Haematol. 2003;16:535–43. doi: 10.1016/s1521-6926(03)00058-6. [DOI] [PubMed] [Google Scholar]
  • 4.Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the acute leukemias. French-American-British (FAB) co-operative group. Br J Haematol. 1976;33:451–8. doi: 10.1111/j.1365-2141.1976.tb03563.x. [DOI] [PubMed] [Google Scholar]
  • 5.Redaelli A, Lee JM, Stephens JM, Pashos CL. Epidemiology and clinical burden of acute myeloid leukemia. Expert Rev Anticancer Ther. 2003;3:695–710. doi: 10.1586/14737140.3.5.695. [DOI] [PubMed] [Google Scholar]
  • 6.Tallman MS, Andersen JW, Schiffer CA, et al. All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood. 2002;100:4298–302. doi: 10.1182/blood-2002-02-0632. [DOI] [PubMed] [Google Scholar]
  • 7.Tallman MS, Nabhan C, Feusner JH, Rowe JM. Acute promyelocytic leukemia: evolving therapeutic strategies. Blood. 2002;99:759–67. doi: 10.1182/blood.v99.3.759. [DOI] [PubMed] [Google Scholar]
  • 8.Grignani F, Fagioli M, Alcalay M, et al. Acute promyelocytic leukemia: from genetics to treatment. Blood. 1994;83:10–25. [PubMed] [Google Scholar]

Articles from Clinics and Practice are provided here courtesy of Multidisciplinary Digital Publishing Institute (MDPI)

RESOURCES